Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03847389 · ClinicalTrials.gov registry record · Phase 1
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
A Phase 1 study, sponsored by Hill Dermaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03847389 is a Phase 1 study that was terminated before completion, run by Hill Dermaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT03847389, a Phase 1 study, was terminated before completion, sponsored by Hill Dermaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Open-Label Study designed to evaluate the HPA axis suppression potential of Clobetasol Topical Oil and pharmacokinetic safety / systemic exposure to clobetasol when Clobetasol Topical Oil is applied to pediatric subjects with moderate to severe atopic dermatitis (AD) under maximal use conditions. The study duration for each subject will be up to 54 days (up to 38 days for Screening assessments, followed by up to 16 days of treatment and follow-up). Additional time will be required for subjects requiring additional hypothalamic-pituitary-adrenal \[HPA\] axis function testing due to an abnormal result at End of Treatment.
Interventions
- DRUG Clobetasol propionate 0.05% Topical Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2020-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03847389
The ClinicalTrials.gov registry entry for NCT03847389 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hill Dermaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clobetasol propionate 0.05% Topical Oil is the first listed.
NCT03847389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03847389 about?
NCT03847389 is a clinical study titled "Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis". Open-Label Study designed to evaluate the HPA axis suppression potential of Clobetasol Topical Oil and pharmacokinetic safety / systemic exposure to clobetasol when Clobetasol Topical Oil is applied to pediatric subjects with moderate to severe atopic dermatitis (AD) under maximal use conditions. T...
What is the current status of trial NCT03847389?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-09-09. Estimated completion is 2020-07-28.
What interventions are being tested in trial NCT03847389?
The interventions under investigation include: Clobetasol propionate 0.05% Topical Oil (DRUG).
Who is sponsoring clinical trial NCT03847389?
This trial is sponsored by Hill Dermaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.